iTeos Therapeutics

General Information


We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. Our innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. 

Employees: 46
Founded: 201
Contact Information
Address 139 Main Street, Cambridge, MA 02142, US
Phone Number (339) 217-0162
Web Address
View Prospectus: iTeos Therapeutics
Financial Information
Market Cap $635.2mil
Revenues $0 mil (last 12 months)
Net Income $-27.9 mil (last 12 months)
IPO Profile
Symbol ITOS
Exchange NASDAQ
Shares (millions): 10.6
Price range $19.00 - $19.00
Est. $ Volume $201.4 mil
Manager / Joint Managers J.P. Morgan/ SVB Leerink/ Piper Sandler
CO-Managers Wedbush Securities
Expected To Trade: 7/24/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change